| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Biotin-aniline targets RNA and DNA in living cells, serving as a probe for capturing subcellular transcriptomes. As a novel APEX2 substrate, it can be used in proximity labeling techniques to identify RNA-protein and DNA-protein interactions. The biotin moiety enables streptavidin-based purification and detection of labeled molecules.
|
|---|---|
| ln Vitro |
In vitro activity of biotin-aniline is demonstrated by its substantially high reactivity towards RNA and DNA. The compound is highly efficient for capturing subcellular transcriptomes in living cells with high spatial specificity. Its reactivity and specificity make it a valuable tool for studying RNA and DNA biology.
|
| ln Vivo |
In vivo activity of biotin-aniline is observed in its use for labeling RNA and DNA in living cells. The compound can be applied to cells or tissues to capture the subcellular transcriptome with high spatial specificity. Its biotin moiety enables subsequent detection and purification of labeled molecules using streptavidin-based methods.
|
| Enzyme Assay |
In vitro enzyme assays for biotin-aniline are not typically performed, as the compound is used as a chemical probe rather than an enzyme inhibitor. Its reactivity with RNA and DNA can be assessed by incubating the compound with nucleic acid samples and detecting biotinylated products using streptavidin-based assays.
|
| Cell Assay |
In vitro cellular assays for biotin-aniline involve treating cells with the compound to allow labeling of RNA and DNA. Labeled nucleic acids are then detected and purified using streptavidin-based methods. The compound can be used in proximity labeling techniques to identify RNA-protein and DNA-protein interactions.
|
| Animal Protocol |
In vivo animal experiments for biotin-aniline are not extensively documented. If used in animal models, typical protocols would involve administering the compound to tissues or organs to label RNA and DNA for subsequent analysis. The compound's biotin moiety enables detection and purification of labeled molecules.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for biotin-aniline are limited. The compound has a molecular weight of 362.49 and a molecular formula of C18H26N4O2S. It is soluble in DMSO at ≥50 mg/mL. It should be stored at 4°C and protected from light. Its ADME properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for biotin-aniline are limited. As a research chemical, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Biotin-aniline (CAS#: 769933-15-5) has the molecular formula C18H26N4O2S and a molecular weight of 362.49. It is a probe with high reactivity towards RNA and DNA, used for capturing subcellular transcriptomes in living cells. It is also a novel APEX2 substrate. Purity is ≥98%. It is for research use only.
|
| Molecular Formula |
C18H26N4O2S
|
|---|---|
| Molecular Weight |
362.49
|
| Exact Mass |
362.177
|
| CAS # |
769933-15-5
|
| PubChem CID |
119548801
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
732.8±60.0 °C at 760 mmHg
|
| Flash Point |
397.0±32.9 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
0.24
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
468
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCC3=CC=C(C=C3)N)NC(=O)N2
|
| InChi Key |
AHRRICHWBPPWDZ-ZOBUZTSGSA-N
|
| InChi Code |
InChI=1S/C18H26N4O2S/c19-13-7-5-12(6-8-13)9-10-20-16(23)4-2-1-3-15-17-14(11-25-15)21-18(24)22-17/h5-8,14-15,17H,1-4,9-11,19H2,(H,20,23)(H2,21,22,24)/t14-,15-,17-/m0/s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-(4-aminophenyl)ethyl]pentanamide
|
| Synonyms |
Biotin-aniline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~689.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7587 mL | 13.7935 mL | 27.5870 mL | |
| 5 mM | 0.5517 mL | 2.7587 mL | 5.5174 mL | |
| 10 mM | 0.2759 mL | 1.3793 mL | 2.7587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
